<DOC>
	<DOCNO>NCT02640664</DOCNO>
	<brief_summary>The purpose study evaluate long term efficacy safety intravitreal ranibizumab compare laser ablation therapy patient treat retinopathy prematurity ( ROP ) core study CRFB002H2301</brief_summary>
	<brief_title>Rainbow Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>The patient successfully complete core study CRFB002H2301 The patient receive study treatment eye baseline study CRFB002H2301 Patient medical condition personal circumstance precludes study participation compliance study procedure , assess Investigator Patient discontinue core study CRFB002H2301 time Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>open-label , long-term , extension study</keyword>
	<keyword>intravitreal ranibizumab</keyword>
	<keyword>laser ablation therapy</keyword>
	<keyword>retinopathy prematurity</keyword>
	<keyword>preterm infant</keyword>
	<keyword>RAINBOW</keyword>
</DOC>